Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
SPOP mutation
i
Other names:
SPOP, Speckle Type BTB/POZ Protein, Speckle-Type POZ Protein, Roadkill Homolog 1, HIB Homolog 1, BTBD32, TEF2, NEDMACE, NEDMIDF, NSDVS1, NSDVS2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
8405
Related biomarkers:
Mutation
Others
‹
›
Associations
(4)
News
Trials
Search handles
@DrYukselUrun
@RohanGarjeMD
@neerajaiims
@shilpaonc
Search handles
@DrYukselUrun
@RohanGarjeMD
@neerajaiims
@shilpaonc
Filter by
Latest
11ms
SPOP Mutations as First Predictive Biomarker for Treatment Selection in De Novo Metastatic Hormone-Sensitive Prostate Cancer @umangtalking @ASCO https://t.co/9kKxD2GZNn (@DrYukselUrun)
11 months ago
Metastases
|
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
1year
La medicina de precisión 🔬🧬 en cáncer de próstata ya es una realidad Un biomarcador predictivo que nos orienta que tratamiento utilizar. SPOP Mutations as First Predictive Biomarker for Treatment Selection in De Novo Metastatic Hormone-Sensitive Prostate Cancer @LuisSalgadoS (@_DrJuanGalvis)
1 year ago
Metastases
|
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
1year
The #ASCOdailynews highlights SPOP mutation as a first biomarker for better response to ARPIs vs. docetaxel in de novo mCSPC. Further investigation of biomarkers is necessary to enhance the personalization of mCSPC treatment @umangtalking @nsayeghmd @Huntsman_GU https://t.co/0ZpUZUQwxJ (@ggebraelmd)
1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
|
docetaxel
1year
Just in #ASCODailyNews 👉SPOP mutation as predictive biomarker for Rx selection for ARSIs in mHSPC #prostatecancer & potential use in “de-escalation”. Excellent article by our star trainee @ggebraelmd 👇 & @Huntsman_GU team @umangtalking @nsayeghmd Cc’ing: @PCF_Science @urotoday… https://t.co/ESKQkrISAZ (@neerajaiims)
1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
1year
I favor ARPi doublets in SPOP mutant mCSPC and favor triplets when there are alterations in any two of TP53, Rb, and PTEN. That approach is not supported by level 1 evidence but is supported by many strands of lower level data. (@AlanBryce9)
1 year ago
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • SPOP (Speckle Type BTB/POZ Protein)
|
TP53 mutation • SPOP mutation
1year
Thought provoking presentation by @neerajaiims focusing on Parp inhibitors, 177LuPSMA, AKT inhibitors, SPOP mutations in prostate cancer! @montypal @PGrivasMDPhD @BrainTumorDoc @MiamiCancerInst #MCIPrecisionOncology symposium (@RohanGarjeMD)
1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
over1year
@GUONCGarciaJA gives a shoutout to @neerajaiims @umangtalking on their work on #SPOP mutations as a predictive biomarker in mHSPC @OncLiveSOSS @RyonGraf @MosheOrnsteinMD @ChrisWeeMD @DrOmarMian @EAntonarakis (@shilpaonc)
over 1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
over1year
SPOP mutations are early event in prostate tumorigenesis & result in ⬆️AR signaling. Due to addiction of mutSPOP to AR signaling, we hypothesized ➡️ ADT+ARAT (but not docetaxel), will be associated with improved outcomes in pts with dn-mCSPC harboring mutSPOP (3/10). @urotoday (@umangtalking)
over 1 year ago
Clinical
|
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
|
docetaxel
over1year
Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel https://t.co/aYH06Fb2WU @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10) (@umangtalking)
over 1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
|
docetaxel
over1year
🧬SPOP mutations were associated with improved outcomes to ADT+androgen receptor-axis-targeted therapies (but not ADT plus docetaxel) in de novo mCSPC 🔶Treatment selection for mCSPC might be chosen accordingly! @umangtalking @OncoAlert #prostatecancer https://t.co/yZWQzxew7h (@DrYukselUrun)
over 1 year ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
|
docetaxel
over1year
#ESMO22 @myESMO Abs# 1373P: In the real-world data, SPOP mutation was found associated with improved survival with ADT+ARAT (but not ADT+docetaxel) in denovo #prostate cancer. https://t.co/RNV2LH3u4c. @neerajaiims @umangtalking @RyonGraf @EAntonarakis @OncoAlert @urotoday (@sahuonc)
over 1 year ago
Clinical • Real-world evidence
|
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
|
docetaxel
over2years
Agree, lots evidence now that SPOP mut = 'good' and tumour suppressor loss = 'bad', but I think @Chris_Barbieri1 would be the first to point out that 10% of men with mCRPC are still dying with SPOP-mutant prostate cancer. How do we push exceptional response to actual cure? (@ResearchWyatt)
over 2 years ago
SPOP (Speckle Type BTB/POZ Protein)
|
SPOP mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login